Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group-Reference-Cited by-同舟云学术

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Published:2009-08-19 Issue:1 Volume:119 Page:127-136
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Inoue Kenichi,Nakagami Kazuhiko,Mizutani Mitsuhiro,Hozumi Yasuo,Fujiwara Yasuhiro,Masuda Norikazu,Tsukamoto Fumine,Saito Mitsue,Miura Shigeto,Eguchi Kenji,Shinkai Tetsu,Ando Masashi,Watanabe Toru,Masuda Noriyuki,Ohashi Yasuo,Sano Muneaki,Noguchi Shinzaburo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-009-0498-7.pdf

Reference17 articles.

1. Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339:974–984

2. Piccart MJ (2001) Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe. Ann Oncol 12(Suppl.1):S89–S94

3. NCCN Clinical Practice Guidelines in Oncology version 1 (2009) Breast cancer. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf

4. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

5. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265–4274

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis;Cancer Innovation;2024-05-22

2. Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure;Journal of the American College of Cardiology;2023-11

3. HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments;Cancers;2023-03-13

4. Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer;The Egyptian Heart Journal;2023-02-13

5. Antibody–drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment;Therapeutic Advances in Medical Oncology;2023-01